HC Wainwright Predicts Lower Earnings for Cogent Biosciences

Key Points

• HC Wainwright lowered its Q4 2026 EPS forecast for Cogent Biosciences to a loss of $0.67 per share from a projected loss of $0.62, while maintaining a Buy rating and a $56 price target.
• Cogent’s latest quarterly loss of $0.59 per share was wider than the consensus estimate of $0.56; its shares were reported down 5.7% and opened at $31.64.
• Analyst sentiment is broadly positive: MarketBeat’s consensus rating is “Moderate Buy,” with an average price target of $53.57, though some firms rate the stock Sell.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Stock analysts at HC Wainwright cut their Q4 2026 EPS estimates for Cogent Biosciences in a research note issued to investors on Monday, November 9th. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings of ($0.67) per share for the quarter, down from their prior forecast of ($0.62). HC Wainwright has a "Buy" rating and a $56.00 price objective on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at $0.19 EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($1.09) EPS.

Other research analysts have also issued reports about the company. Guggenheim increased their price objective on Cogent Biosciences from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Wall Street Zen downgraded Cogent Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, September 5th. Piper Sandler upped their price target on Cogent Biosciences from $52.00 to $55.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Wedbush reiterated an "outperform" rating and set a $55.00 price target on shares of Cogent Biosciences in a report on Wednesday, September 16th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Cogent Biosciences in a report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cogent Biosciences presently has an average rating of "Moderate Buy" and a consensus target price of $53.57.

Cogent Biosciences Stock Down 5.7%

COGT stock opened at $31.64 on Wednesday. The firm has a market cap of $5.49 billion, a PE ratio of -14.06 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 13.57 and a current ratio of 10.99. The firm's 50 day moving average price is $31.74 and its 200-day moving average price is $35.44. Cogent Biosciences has a one year low of $27.74 and a one year high of $43.73.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The technology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03).

Hedge Funds Weigh In On Cogent Biosciences

Hedge funds have recently made changes to their positions in the stock. J.Safra Asset Management Corp acquired a new stake in Cogent Biosciences in the 2nd quarter valued at approximately $27,000. Integrated Wealth Concepts LLC acquired a new position in Cogent Biosciences during the second quarter worth $29,000. Parallel Advisors LLC purchased a new position in shares of Cogent Biosciences during the first quarter worth $39,000. Quantbot Technologies LP purchased a new position in shares of Cogent Biosciences during the second quarter worth $53,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Cogent Biosciences by 127.5% during the first quarter. EverSource Wealth Advisors LLC now owns 1,611 shares of the technology company's stock worth $62,000 after buying an additional 903 shares during the period.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company's lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.